Exercise electrocardiographic responses and serum cystatin C levels among metabolic syndrome patients without overt diabetes mellitus by Tanindi, Asli et al.
© 2011 Tanindi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2011:7 59–65
Vascular Health and Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
59
ORiginAL ReseARcH
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/VHRM.S16638
exercise electrocardiographic responses  
and serum cystatin c levels among metabolic 
syndrome patients without overt diabetes mellitus
Asli Tanindi1 
Hilal Olgun1 
Ayse Tuncel2 
Bulent celik3 
Hatice Pasaoglu2 
Bulent Boyaci1
1Department of cardiology, 
2Department of Medical Biochemistry, 
Faculty of Medicine, 3Department of 
statistics, Faculty of Health sciences, 
gazi University, Ankara, Turkey
correspondence: Asli Tanindi 
gazi University Ho Vspital, Department  
of cardiology, Besevler, 06500  
Ankara, Turkey 
Tel +903122025629 
Mobile +905324642945 
email aslitanindi@gmail.com
Objectives: An impaired heart rate response during exercise (chronotropic incompetence) 
and an impaired heart rate recovery (HRR) after exercise are predictors of cardiovascular risk 
and mortality. Cystatin C is a novel marker for cardiovascular disease. We aimed to investigate 
exercise electrocardiographic responses in patients with metabolic syndrome who were without 
overt diabetes mellitus, in addition to the association of serum cystatin C levels with the exercise 
electrocardiographic test results.
Method: Forty-three consecutive patients admitted to a cardiology outpatient clinic without 
angina pectoris were recruited if they met criteria for metabolic syndrome but did not have 
overt diabetes mellitus. Serum cystatin C levels were measured, and all participants underwent 
exercise electrocardiographic testing. Patients who were found to have ischemia had a coronary 
angiography procedure.
Results: The mean cystatin C level of patients was higher in metabolic syndrome group than 
healthy controls (610.1 ± 334.02 vs 337.3 ± 111.01 µg/L; P , 0.001). The percentage of patients 
with ischemia confirmed by coronary angiography was 13.9% in the metabolic syndrome group. 
Cystatin C levels in the ischemic patients of the metabolic syndrome group were higher than that 
in nonischemic patients (957.00 ± 375.6 vs 553.8 ± 295.3 µg /L; P = 0.005). Chronotropic incom-
petence was observed in 30.2% of the patients with metabolic syndrome compared with 16.7% 
in the control group (P = 0.186). Chronotropic response indices were 0.8 ± 0.18 versus 0.9 ± 0.10 
for the two groups, respectively (P = 0.259). HRR was significantly lower in the metabolic 
syndrome patients compared with the controls (20.1 ± 8.01 vs 25.2 ± 4.5 per min; P , 0.001), 
and the ST-segment adjustment relative to heart rate(ST/HR index ratio) was 1.4 ± 1.34 versus 
0.4 ± 0.31 µV/beat (P , 0.001), respectively. Cystatin C was negatively correlated with the 
chronotropic response index (CRI) and HRR and was positively correlated with ST/HR index 
in the entire study population (R = −0.658, −0.346, 0.388, respectively; P , 0.05).
Conclusions: A substantial proportion of metabolic syndrome patients without overt dia-
betes mellitus had silent coronary ischemia in addition to impairment of objective exercise 
electrocardiographic parameters. In the metabolic syndrome patients without overt diabetes 
mellitus, cystatin C levels were found to be elevated and the elevation was more pronounced in 
the subgroup with silent ischemia. Cystatin C was also correlated with HRR and CRI.
Keywords: exercise electrocardiography, metabolic syndrome, silent ischemia, cystatin C
Introduction
Metabolic syndrome, which consists of abdominal obesity, low levels of high-density 
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has become an increasingly important risk factor for 
  cardiovascular morbidity and mortality.1 Recently, it was 
reported that exercise electrocardiographic responses are 
strong predictors of cardiovascular risk and mortality in 
the presence of metabolic syndrome components and this 
relationship increased with the number of present metabolic 
syndrome components.2
Chronotropic incompetence, (CI) defined as ‘the inabil-
ity to achieve 85% of the age-predicted maximum heart 
rate’, has been shown to be associated with cardiovascular 
risk and cardiac mortality.3 It has also been reported that 
autonomic nervous system–related chronotropic incompe-
tence during exercise is influenced by endothelial dysfunc-
tion as   represented by flow-mediated dilation.4 Heart rate 
recovery (HRR), another parameter evaluated during exercise 
  testing, is a marker of impaired parasympathetic reactivity 
and has been studied in patients with metabolic syndrome 
or metabolic risk factors.5,6
Cystatin C, which is a novel indicator of renal glomeru-
lar filtration rate, has recently been shown to be associated 
with metabolic syndrome, diabetes, and prediabetes.7–9 
Cystatin C levels have been found to be superior to creatinine 
or c  reatinine-based formulas for the prediction of cardio-
vascular events and all-cause mortality.10 The association 
of cystatin C with insulin resistance, metabolic syndrome, 
and endothelial dysfunction,11 in addition to a number of 
inflammatory biomarkers,12,13 is the likely link between 
cardiovascular disease and cystatin C.
We chose to study metabolic syndrome patients without 
known coronary artery disease or overt diabetes mellitus 
because diabetes is considered to be a coronary artery disease 
risk equivalent. We sought to investigate the impact of meta-
bolic syndrome on exercise electrocardiographic stress test 
parameters, especially regarding chronotropic incompetence, 
chronotropic response index (CRI), and HRR. In addition, we 
examined the association of cystatin C in metabolic syndrome 
without overt diabetes and the prementioned exercise test 
parameters regarding the early detection of cardiovascular 
disease and risk prediction.
Patients and methods
Forty-three consecutive patients admitted to the outpatient 
clinic of the Cardiology Department of Gazi University 
Faculty of Medicine Hospital between September 2009 
and February 2010 were recruited only if they did not have 
angina pectoris or any angina equivalent and if they met the 
criteria for metabolic syndrome but did not exhibit overt 
diabetes mellitus. Patients were enrolled if they had impaired 
glucose tolerance. Metabolic syndrome was defined according 
to the American Heart Association and the National Heart, 
Lung, and Blood Institute criteria.14 Patients with three or 
more of the following risk factors were considered to have 
metabolic   syndrome: 1) abdominal obesity (.102 cm in men 
and .88 cm in women), 2) low high-density lipoprotein levels 
(,40 mg/dL for men and ,50 mg/dL for women), 3) high 
triglyceride levels (.150 mg/dL), 4) high fasting plasma 
glucose levels (.100 mg/dL), and 5) high blood pressure 
($130/85 mm Hg). Baseline biochemical examinations 
were performed after 12 h of fasting. Blood pressures were 
recorded in the outpatient clinic after 10 min of rest. Waist 
circumference was measured at the level of the umbilicus 
using a standard anthropometric tape measure. Patients 
with known diabetes mellitus, previous coronary artery 
disease, cerebrovascular disease, moderate to severe valvular 
pathology, heart failure, hyperthyroidism, hypothyroidism, 
left bundle branch block, Wolff–Parkinson–White syndrome, 
any rhythm other than sinus rhythm on baseline electrocardi-
ography (atrial fibrillation, atrial flutter, etc.), impaired renal 
function (serum creatinine .1.4 mg/dL), or impaired liver 
function (aspartate aminotransferase/alanine aminotransferase 
elevation .3 times the upper limit) were excluded.
The control group comprised healthy individuals admitted 
to the institutional blood transfusion center of the hospital as 
voluntary blood donors. The study was conducted according 
to the guidelines of the Declaration of Helsinki, and it was 
approved by the Institutional Ethics Committee. All of the 
participants provided written informed consent.
Blood samples for cystatin C measurements were centri-
fuged and kept at −80°C until they were measured using 
the Human Cystatin C ELISA assay (BioVendor, Modrice, 
Czech Republic) according to the manufacturer’s protocols. 
Both intra-assay and inter-assay coefficient of variations 
were ,5%.
Exercise testing was performed according to the Bruce 
protocol with an AT-10 Exercise Testing System (  Schiller, 
Baar, Switzerland). A 12-lead electrocardiography study 
was obtained throughout the procedure, and heart rate 
was   monitored from the beginning of testing to the end of 
the recovery period. Blood pressure measurements were 
made at the beginning of testing, at every stage, and during 
the recovery period. The target heart rate for each   participant 
was   calculated before the procedure according to the 
following formula for age-predicted maximum heart rate: 
220 − age. Exercise capacity was represented as the maximal 
metabolic equivalent (MET) achieved during exercise. 
The Duke score, which has been validated as an important Vascular Health and Risk Management 2011:7
Table 1 Baseline characteristics of the study population
MS (+) (n = 43) MS (-) (n = 30) P
Age 52.4 ± 10.58 38.0 ± 6.489 0.000
gender (M/F) (%) 10/33 (23.3/76.7) 11/19 (36.7/63.3) 0.213
smoker (%) 34.9 40.0 0.656
Family history (%) 23.3 26.7 0.739
Drugs used
 β -blocker (%) 10.6 6.7 0.114
  Ace i (%) 58.1 16.7 0.000
  AsA (%) 14.0 10.0 0.613
  statin (%) 9.3 13.3 0.588
ecg ischemia (%) 16.3 – –
BMi 32.6 (5.17) 25.7 (1.94) 0.000
Waist 
circumference
108.0 (11.80) 85.0 (6.72) 0.000
Hb 13.6 (1.59) 13.2 (1.14) 0.300
WBc 7308.1 (1737.20) 7294.0 (1102.72) 0.969
Plt 273,069.8  
(65,653.27)
297,333.3  
(60,149.43)
0.112
Fasting glucose 102.9 (9.12) 88.5 (10.45) 0.000
BUn 14.5 (3.86) 27.9 (3.03) 0.000
creatinine 0.8 (0.16) 0.8 (0.15) 0.207
Uric acid 4.9 (1.42) 4.3 (0.35) 0.029
HDL 41.5 (7.74) 50.2 (7.88) 0.000
LDL 129.9 (37.43) 130.4 (8.93) 0.937
Tg 181.8 (63.36) 149.0 (13.83) 0.007
Abbreviations: Ms, metabolic syndrome; Ace, angiotensin-converting enzyme; 
AsA,  acetylsalicylic  acid;  ecg,  electrocardiogram;  BMi,  body  mass  index; 
Hb, hemoglobin; WBc, white blood cells; Plt, platelets; BUn, blood urea nitrogen; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; Tg, triglycerides.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
61
Metabolic syndrome, exercise electrocardiography, and cystatin c
predictor of mortality,15 was calculated for each participant 
according to the following   formula: Duke treadmill score 
(DTS) = the duration of exercise (in minutes) − (5 × maximal 
ST segment deviation) − (4 × angina score). (Angina score: 
0 = no angina, 1 = nontest-limiting angina, 2 = exercise-
limiting angina.) Chronotropic incompetence was defined 
as a ‘failure to achieve 85% of age predicted maximum 
heart rate’. The CRI, which is a measure of maximal heart 
rate in relation to   chronotropic reserve, was calculated 
using the formula: (peak heart rate − resting heart rate)/(age 
− age predicted maximum heart rate − resting heart rate).16 
HRR was defined as a decrease in the heart rate from peak 
exercise rate to 1 min after cessation of exercise.17 Exercise 
test results regarding ischemia were interpreted as either 
ischemic, equivocally ischemic, or normal. The criteria for 
classifying an exercise stress test as ‘ischemic’ have been 
provided elsewhere.18 We categorized an exercise stress test 
result as ‘equivocal’ if ST segment depressions of 0.5–1 mm 
were observed to persist for more than 0.08 sec. Participants 
with ischemic or equivocal test results underwent coronary 
angiography by Judkins technique, which was performed 
using a Toshiba Infinix CSI device (Toshiba, Tokyo, Japan) 
using 6F catheters via femoral route. Coronary angiographic 
evaluation was performed by two blinded c  ardiologists 
offline; in the case of any disagreement, a third cardiologist 
was consulted. The presence of .70% coronary stenosis was 
defined as definite ischemia.
statistical analysis
SPSS for Windows (version 15; SPSS, Chicago, IL) was 
used for statistical analyses. Continuous variables, such as 
cystatin C levels, CRI, HRR, and the ST/HR index, were 
expressed as means ± standard deviation, whereas percentages 
and frequencies were used to express categorical variables, 
such as the presence of ischemia or metabolic syndrome. A 
χ2 test and Fischer’s exact test were used for the analysis of 
categorical variables. For continuous variables, parametric test 
conditions were first tested. The Shapiro–Wilk test was used 
to examine whether continuous variables were normally dis-
tributed. For the analysis of the difference between two groups, 
Student’s t-test and Mann–Whitney U test were employed 
according to the parametric test conditions. The degree of 
association between continuous variables was calculated by 
a Spearman’s ‘rho’ correlation coefficient. The area under 
curve (AUC) and 95% confidence intervals for cystatin C were 
evaluated by receiver operating characteristic (ROC) analysis. 
The best cut-off point for cystatin C was also calculated. A P 
value , 0.05 was considered to be statistically significant.
Results
Baseline characteristics of the study population are provided 
in Table 1. The mean age of metabolic syndrome patients 
(52.4 ± 10.5) was higher than the control group (38.0 ± 6.5), 
whereas the ratio of males to females were comparable 
(23.3% vs 36.7%, P = 0.213). The mean cystatin C levels were 
higher in metabolic syndrome patients than in healthy con-
trols (610.1 ± 334.02 vs 337.3 ± 111.01 µg /L; P , 0.001). 
When a ROC curve analysis was performed, the cut-off value 
for cystatin C was 374.5 µg /L (Figure 1). The AUC was 0.824 
(95% CI 0.728–0.921, P , 0.001). According to this cut-off 
point, 81.4% of the patients with metabolic syndrome had 
‘high’ cystatin C levels, whereas only 23.3% of the patients 
without metabolic syndrome had levels .374.5 µg /L. When 
cystatin C levels were grouped according to the number of 
metabolic syndrome components present, it was found  that 
cystatin C levels increased with the number of components 
(Table 2). However, the difference in cystatin C levels of 
patients who met at least three criteria for metabolic syn-
drome was nonsignificant.
Of the patients with metabolic syndrome, 55.8% completed 
the exercise test at stage III, and 63.4% of healthy controls 
achieved the same level. In contrast, 14% of metabolic Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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syndrome patients and 33% of healthy controls reached 
stage IV. Table 3 shows the exercise electrocardiographic 
results of the study and control groups. Chronotropic incom-
petence was observed in 30.2% of patients with metabolic syn-
drome compared with 16.7% in the control group (P = 0.186). 
Chronotropic response indices were 0.8 ± 0.18 versus 
0.9 ± 0.10, respectively (P = 0.259). HRR was significantly 
lower in the metabolic syndrome patients compared with the 
controls (20.1 ± 8.01 vs 25.2 ± 4.5 per min, P , 0.001). The 
ST/HR index ratio was 1.4 ± 1.34 versus 0.4 ± 0.31 µV/beat, 
respectively (P , 0.001). Table 4 shows the results from 
the exercise test regarding ischemia (ischemic, normal, or 
equivocal). The percentage of patients with an equivocal or 
ischemic exercise test was 30.2% in the metabolic syndrome 
population, but only 13.9% of metabolic syndrome patients 
had definite ischemia detected by coronary angiography. None 
of the participants in the control group had definite ischemia. 
Table 5 shows the exercise test parameters of metabolic 
syndrome patients and the entire population with or without 
ischemia. We were unable to show significant differences 
in the mean CRI and the HRR time between ischemic and 
nonischemic patients within the metabolic syndrome group; 
however, these parameters were significantly different in the 
entire study population.
Cystatin C levels in the ischemic patients of the metabolic 
syndrome group were higher than levels in the nonischemic 
patients (957.00 ± 375.6 vs 553.8 ± 295.3 µg /L; P = 0.005). 
Cystatin C was negatively correlated with the CRI and HRR 
and was positively correlated with the ST/HR index in entire 
study population (R = −0.658, R = −0.346, and R = 0.388, 
respectively; P , 0.05). When patients with metabolic 
syndrome were separately evaluated, cystatin C levels were 
negatively correlated with the CRI (R = −0.737, P , 0.05) 
(Figure 2), but the correlation with HRR and the ST/HR 
index did not reach statistical significance.
Discussion
The major finding of this study was the presence of silent 
ischemia in 13.9% of patients with metabolic syndrome but 
without overt diabetes mellitus. The mean cystatin C level 
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Figure 1 Receiver operating characteristic (ROc) curve analysis for cystatin c 
levels. The cut-off point for cystatin c was 374.5 µg /L.
Table 2 Mean cystatin c levels with respect to the number of 
metabolic syndrome components present
No. of metabolic 
syndrome  
components
N Cystatin C  
μg/L (mean)
SD Min Max
none 8 358.50 84.490 223 488
1/5 16 305.44 83.034 126 456
2/5 6 393.83 181.645 283 754
3/5 16 613.63 379.026 261 1335
4/5 19 627.16 318.695 224 1348
5/5 8 562.50 311.446 274 1137
Total 73 497.97 297.178 126 1348
Note: The difference between 1 criterion and 3 criteria and the difference between 
1 criterion and 4 criteria are statistically significant (P , 0.05).
Abbreviation: sD, standard deviation.
Table 3 exercise electrocardiographic test results of participants 
with and without metabolic syndrome
MS (+) (n = 43) MS (-) (n = 30) P
Duke score   2.3 ± 4.27   8.8 ± 3.09 0.000
MeT   8.3 ± 1.69   9.6 ± 1.59 0.001
exercise duration (min)   6.5 ± 1.71   10.5 ± 1.50 0.000
initial HR   90.0 ± 13.20   78.0 ± 7.34 0.000
Max HR 154.4 ± 20.99 170.3 ± 13.93 0.001
APMHR 167.1 ± 10.99 181.9 ± 6.50 0.000
cRi   0.8 ± 0.18   0.9 ± 0.10 0.259
HRR   20.1 ± 8.01   25.2 ± 4.50 0.000
sT/HR   1.4 ± 1.34   0.4 ± 0.31 0.000
Abbreviations: MeT, metabolic equivalent; HR, heart rate; APMHR, age-predicted 
maximum  heart  rate;  cRi,  chronotropic  response  index;  sT/HR,  sT-HR  index; 
Ms, metabolic syndrome.
Table 4 exercise test results of the study population with and 
without metabolic syndrome
Exercise test results Metabolic syndrome
Present (n = 43) Absent (n = 30)
ischemia (n/%) 6 (13.9) –
normal (n/%) 30 (69.7) 25 (83.3)
equivalent (n/%) 7 (16.4) 5 (16.7)Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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was higher in metabolic syndrome patients than in healthy 
controls. Moreover, cystatin C levels in ischemic patients 
within the metabolic syndrome group were higher than 
in nonischemic patients. The 13.9% prevalence of silent 
ischemia in our study is lower than percentages reported 
for diabetic patients.19,20 To our knowledge, this study is the 
first to report the frequency of silent ischemia in metabolic 
syndrome patients without overt diabetes mellitus. Although 
our report highlights the presence of coronary ischemia 
in a substantial proportion of the target population, this 
issue should be a topic for future research in larger study 
populations to confirm these results.
When objective parameters for the interpretation of 
exercise stress testing were analyzed, we observed that HRR 
was significantly impaired when compared with healthy 
controls. However, the difference between the percentage of 
participants with and without chronotropic incompetence and 
the chronotropic response indices of participants with or with-
out metabolic syndrome did not reach statistical significance. 
Cystatin C was negatively correlated with the CRI and HRR 
and was positively correlated with ST/HR index.
Cystatin C, a low molecular weight plasma protein that 
functions as an inhibitor of cysteine proteases, is produced 
by all nucleated cells, freely filtered by renal glomeruli 
and metabolized in the proximal tubules.21 Cystatin C has 
been shown to be a strong independent risk factor for 
cardiovascular mortality and a powerful prognostic factor 
among patients with known coronary artery disease.22,23 
High cystatin C concentrations also predict cardiovascular 
risks in patients without microalbuminuria and with normal 
glomerular filtration rates, in addition to patients with renal 
damage.10 We have demonstrated an association between 
cystatin C and the presence of metabolic syndrome without 
overt diabetes mellitus. In addition, we report a positive 
correlation between this molecule and silent ischemia as 
well as some of the above-mentioned exercise electrocardio-
graphic parameters. Recently cystatin C has been reported 
to be associated with endothelial dysfunction as represented 
by flow-mediated dilatation,24 in addition to its correlation 
with insulin resistance and inflammatory biomarkers.12,13,25 
Although we cannot definitely suggest a causal relationship 
between cystatin C and silent ischemia or any of the exercise 
electrocardiographic findings due to the cross-sectional 
design of the study, endothelial dysfunction probably con-
stitutes an important role in this process due to the fact that 
endothelium is the chief regulator of vascular homeostasis26 
and plays a role in all stages of atherosclerosis.27 In a recent 
study, 899 patients with known coronary artery disease and 
stable angina pectoris had underwent an exercise treadmill 
test with stress echocardiography, and elevated levels of 
cystatin C were associated with inducible ischemia.28
HRR after maximal exercise testing is a predictor of 
mortality and cardiovascular disease independent of the 
angiographic severity of coronary artery disease.29,30 Studies 
investigating HRR have expanded to include diabetic patients, 
patients with insulin resistance, and patients with metabolic 
risk factors.31–34 It has been suggested that short-term HRR 
Table  5  exercise  electrocardiographic  test  results  according 
to the presence or absence of ischemia in metabolic syndrome 
patients and the entire study population
Ischemia N Mean SD U P
MeT s(+) only
  cRi (−) 37 0.84 0.166 61.00 0.083
(+) 6 0.66 0.233
  HRR (beats/min) (−) 37 20.70 8.299 75.00 0.220
(+) 6 16.33 4.885
  sT/HR (µV/beat) (−) 37 1.14 1.127 32.00 0.004
(+) 6 2.95 1.612
entire population
  cRi (−) 67 0.86 0.140 103.00 0.046
(+) 6 0.66 0.242
  HRR (beats/min) (−) 67 22.70 7.173 83.50 0.018
(+) 6 16.33 4.885
  sT/HR (µV/beat) (−) 67 0.79 0.940 38.00 0.001
(+) 6 2.95 1.612
Abbreviations:  MeT,  metabolic  equivalent;  cRi,  chronotropic  response  index; 
HRR, heart rate recovery.
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Figure  2  scatter  plot  showing  the  correlation  between  cystatin  c  and  the 
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(1-min HRR) reflects cardiac parasympathetic outflow, 
whereas a subsequent slow heart rate decay is associated 
with the withdrawal of sympathetic activity.35 There have 
been studies suggesting that autonomic dysfunction is 
associated with hyperinsulinemia, insulin resistance, and 
obesity36,37 and that the central nervous system contributes 
to the development of metabolic syndrome. However, the 
CARDIA study has revealed that a slower HRR does not pre-
cede the development of the metabolic syndrome, but, rather 
appears after components of the syndrome are present.5 In 
a recent study by Giallauria et al, in a population consisting 
of young women with polycystic ovary syndrome, abnormal 
HRR was associated with elevated white blood cell counts 
and C-reactive protein, a well-known inflammatory marker.38 
Another report demonstrated that in patients with established 
coronary artery disease, Cystatin C concentrations were 
associated with decreased exercise capacity and lower HRR;39 
however, the participants in that study were largely elderly 
men. Our results support previous studies that suggest an 
impairment of HRR in the presence of metabolic disturbances 
or inflammation, but this relationship has now been demon-
strated for the first time in an asymptomatic patient group 
with metabolic syndrome, without overt diabetes.
Chronotropic incompetence is defined by an attenuated 
heart rate response to exercise that has been shown to predict 
cardiovascular risk and mortality in healthy populations; 
even after adjusting for age, standard risk factors, and ST 
segment changes during exercise.40 Chronotropic incompe-
tence has been believed to reflect a modulation of autonomic 
tone. It has been suggested that frequent activation of sym-
pathetic nerves alters β-adrenergic sensitivity and causes 
postsynaptic β desensitization, which subsequently leads 
to chronotropic incompetence during exercise.41,42 Another 
proposed mechanism is compensatory vagal hyperactivity 
during exercise.43 Huang et al reported that among patients 
who had undergone a treadmill exercise test for typical and 
atypical angina pectoris, the subgroup with chronotropic 
incompetence had endothelial dysfunction and enhanced 
systemic inflammation.4 We observed that cystatin C was 
correlated with chronotropic incompetence and the CRI, 
although the cross-sectional design of this study prevents a 
causal interpretation of this relationship.
In conclusion, in metabolic syndrome patients without 
overt diabetes mellitus, we have demonstrated the presence 
of silent ischemia in a substantial percentage of the study 
population as well as impairment in most of the exercise 
electrocardiographic parameters and an association between 
them and elevated serum cystatin C levels. Cystatin C, an 
emerging biomarker for cardiovascular morbidity and 
mortality, may be used to identify higher risk subgroups 
within asymptomatic metabolic syndrome patients. These 
patients require aggressive risk factor modification and 
antiatherosclerotic treatment. Our findings are, therefore, 
significant, especially for clinicians and practitioners who 
often treat these patients in their clinical practice.
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